The FDA has approved the first drug made by a 3D printer
3D printing, a technology still in search of a market, may have just found a home in the world of medicine. The US Food and Drug Administration approved an epilepsy medicine called Spritam that is made by 3D printers …
Context & Ripple Effects
In March 2015, Carbon3D demonstrated a resin-growth printing method 25-100x faster than conventional layer-by-layer printing — evidence that additive manufacturing was maturing beyond prototyping but still lacking a killer market. This approval gives the technology one: Spritam, an epilepsy medicine, becomes the first drug the FDA has cleared that is manufactured by 3D printers rather than pressed into tablets.
The significance runs through the regulator as much as the printer. The same FDA that two years later would approve the first digital pill with an embedded ingestion sensor, and that later cleared AI-designed compounds like the one Exscientia developed in under a year, here extends its review playbook to a novel manufacturing process — establishing that a printed dosage form can meet pharmaceutical standards at all.
First-order effects
- Spritam's maker gains a legally sellable product and a regulatory first-mover position, while epilepsy patients get a newly formulated treatment option produced via additive manufacturing.
- The FDA now has an approved precedent for evaluating drugs defined by their production method, giving its reviewers a template for the next non-traditional manufacturing submission.
Second-order effects
- Industrial 3D printing firms gain validation for a regulated-medical market: the pivot proved durable five years later when Carbon raced to produce FDA-approved equipment for COVID and Stratasys and Protolabs printed face shields and medical gear, suggesting printer vendors will keep courting healthcare customers.
- Traditional tablet-press manufacturers and generic-drug producers face a new competitive axis — formulation and printability — rather than price alone, once printed dosing proves economical at scale.
Third-order effects
- If the pattern holds, drug manufacturing drifts toward on-demand, digitally specified production, weakening the fixed-factory model that has defined pharmaceutical supply chains.
- The deeper shift is institutional: the FDA is consolidating its role as the pacing gatekeeper for every technology — printed drugs, sensor pills, implanted devices — seeking to cross from industrial novelty into medicine.
The trend: Regulators, led by the FDA, are becoming the decisive bottleneck-and-accelerator determining which emerging manufacturing and computing technologies get to become medical products.